No headlines found.
Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million
Globe Newswire (Mon, 1-Apr 7:00 AM ET)
Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024
Globe Newswire (Thu, 21-Mar 4:05 PM ET)
Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial
Globe Newswire (Thu, 7-Mar 4:05 PM ET)
Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Conference
Globe Newswire (Mon, 26-Feb 4:05 PM ET)
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
Xtant Medical Hldgs trades on the AMEX stock market under the symbol XTNT.
As of April 19, 2024, XTNT stock price declined to $0.83 with 122,950 million shares trading.
XTNT has a beta of 0.93, meaning it tends to be less sensitive to market movements. XTNT has a correlation of 0.03 to the broad based SPY ETF.
XTNT has a market cap of $107.99 million. This is considered a Micro Cap stock.
Last quarter Xtant Medical Hldgs reported $28 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.01.
In the last 3 years, XTNT stock traded as high as $2.38 and as low as $.43.
The top ETF exchange traded funds that XTNT belongs to (by Net Assets): VTI, VXF.
XTNT has outperformed the market in the last year with a return of +32.7%, while the SPY ETF gained +21.2%. However, in the most recent history, XTNT shares have underperformed the stock market with its stock returning -23.9% in the last 3 month period and -16.7% for the last 2 week period, while SPY has returned +4.3% and -3.5%, respectively.
XTNT support price is $.78 and resistance is $.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XTNT stock will trade within this expected range on the day.